亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results

医学 威尼斯人 慢性淋巴细胞白血病 内科学 人口 不利影响 苯达莫司汀 肿瘤科 恶心 进行性疾病 胃肠病学 白血病 化疗 环境卫生
作者
Mazyar Shadman,Talha Munir,Shuo Ma,Masa Lasica,Monica Tani,Tadeusz Robak,Ian W. Flinn,Jennifer R. Brown,Paolo Ghia,Emmanuelle Ferrant,Constantine S. Tam,Wojciech Janowski,Wojciech Jurczak,Linlin Xu,Tian Tian,Marcus Lefebure,Stephanie Agresti,Jamie Hirata,Alessandra Tedeschi
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (21): 2409-2417 被引量:24
标识
DOI:10.1200/jco-25-00758
摘要

PURPOSE Several chronic lymphocytic leukemia (CLL) studies have demonstrated promising efficacy with the combination of BCL2 and Bruton tyrosine kinase inhibitors; however, patients with CLL with del(17p) and/or TP53 mutation ( TP53 mut) comprised a small percentage of study populations or were excluded entirely. The purpose of the SEQUOIA Arm D cohort was to evaluate the combination of zanubrutinib + venetoclax in treatment-naïve (TN) patients with CLL/small lymphocytic lymphoma (SLL), in a large population of patients with TP53 -aberrant disease. PATIENTS AND METHODS Arm D is a nonrandomized cohort of patients aged 65 years and older (or 18-64 years with comorbidities). Patients received zanubrutinib from cycle 1 and venetoclax from cycle 4 (ramp-up) to cycle 28, followed by continuous zanubrutinib monotherapy until progressive disease (PD), unacceptable toxicity, or meeting undetectable minimal residual disease (uMRD)-guided stopping criteria. RESULTS Between November 2019 and July 2022, 114 patients were enrolled: 66 (58%) with TP53 -aberrant disease, 47 (41%) without TP53 -aberrant disease, and 1 with missing TP53 results. At a median follow-up of 31.2 months, 85 patients (75%) remained on zanubrutinib monotherapy; 29 patients (25%) discontinued zanubrutinib because of adverse event, uMRD-guided stopping criteria, PD, or other. In the intention-to-treat population, 59% of patients achieved peripheral blood uMRD. The 24-month progression-free survival estimate was 92% (95% CI, 85% to 96%). The most common any-grade treatment-emergent AEs (TEAEs) were COVID-19 (54%), diarrhea (41%), contusion (32%), and nausea (30%). The most common grade ≥3 TEAEs were neutropenia (17%), hypertension (10%), diarrhea (6%), and decreased neutrophil count (6%). CONCLUSION Zanubrutinib + venetoclax demonstrated impressive efficacy and a favorable safety profile in patients with TN CLL/SLL, regardless of the presence of TP53 -aberrant disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
晚风发布了新的文献求助10
3秒前
萧雨墨发布了新的文献求助10
3秒前
10秒前
elfriede完成签到 ,获得积分10
16秒前
18秒前
20秒前
21秒前
123发布了新的文献求助10
22秒前
小蘑菇的应助被biubiu采纳,获得10
26秒前
懵懂的念波完成签到,获得积分10
27秒前
英俊的铭的应助被123采纳,获得10
30秒前
36秒前
领导范儿的应助被晚风采纳,获得10
39秒前
41秒前
DDDL发布了新的文献求助10
42秒前
leo发布了新的文献求助10
44秒前
48秒前
49秒前
晚风发布了新的文献求助10
53秒前
CAOHOU的应助被白华苍松采纳,获得10
53秒前
萧雨墨发布了新的文献求助10
54秒前
57秒前
57秒前
58秒前
fantasy的应助被科研通管家采纳,获得10
58秒前
1分钟前
leo完成签到,获得积分10
1分钟前
1分钟前
amiee发布了新的文献求助10
1分钟前
1分钟前
wuyp发布了新的文献求助10
1分钟前
善良的金鱼完成签到,获得积分10
1分钟前
慕青的应助被踏实的聪健采纳,获得10
1分钟前
1分钟前
所所的应助被amiee采纳,获得10
1分钟前
1分钟前
苗苗发布了新的文献求助10
1分钟前
Orange的应助被Balloon采纳,获得10
1分钟前
1分钟前
高速公鹿完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190078
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21851985
捐赠科研通 7788239
什么是DOI,文献DOI怎么找? 3436236
关于科研通互助平台的介绍 2559951
邀请新用户注册赠送积分活动 2482818